GeneMatrix Q1 Sales Slightly Up, Operating Loss Improves

Q1 2026 revenue KRW 2.52bn (vs KRW 2.50bn YoY, +0.9%), operating loss KRW 0.33bn (vs KRW 0.79bn loss in Q1 2025, narrower)
Net loss KRW 0.22bn (vs KRW 0.79bn), significant improvement
R&D cost KRW 0.79bn (31.5% of revenue), slightly down from KRW 0.85bn YoY
Accumulated deficit KRW 23.6bn, no dividend
Obtained CE-IVDR certification for key products (2025), IND approval for Hepatitis A vaccine Phase 1 (Apr 2025)
Debt ratio 56.7%, cash & equivalents KRW 15.3bn, short-term borrowings KRW 3.6bn